ACHIEVE LIFE SCIENCES, INC.
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
ACHV | NDAQ
Overview
Corporate Details
- ISIN(s):
- US0044685008
- LEI:
- Country:
- United States of America
- Address:
- 22722 29TH DR. SE, 98021 SEATTLE
- Website:
- https://achievelifesciences.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to addressing the global nicotine dependence epidemic. The company's core focus is the development and commercialization of its lead product candidate, cytisinicline, a plant-based alkaloid intended for smoking cessation and nicotine addiction. Following two successful Phase 3 studies, the company's New Drug Application (NDA) for cytisinicline was accepted for review by the U.S. Food and Drug Administration (FDA). If approved, cytisinicline has the potential to become the first new FDA-approved treatment option for smoking cessation in nearly two decades.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ACHIEVE LIFE SCIENCES, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ACHIEVE LIFE SCIENCES, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ACHIEVE LIFE SCIENCES, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
